Histone acetyltransferase (HAT) inhibitor and use thereof

1. A compound represented by formula Ig or Ih, a pharmaceutically acceptable salt, stereoisomer, enantiomer, diastereomer, atropisomer, racemate, polymorphs, solvate or isotopically labeled compound thereof:

wherein

R 5 is hydrogen, halogen or C 1 -C 6 alkyl;

X 2 is independently —C(R 2 )(R 3 )—, —O—, —N(R 4 )—, or —S(O) n1 —;

R 2 and R 3 are each independently hydrogen, deuterium, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, or C 3 -C 6 cycloalkyl;

R 4 is independently hydrogen, C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, —C(═O)(C 1 -C 6 alkyl), —S(O) 2 (C 1 -C 6 alkyl), —C(═O)(C 3 -C 6 cycloalkyl), or —S(O) 2 (C 3 -C 6 cycloalkyl);

R 13 and R 14 are each independently hydrogen, deuterium, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, or C 3 -C 6 cycloalkyl;

R 16 and R 17 are each independently hydrogen, deuterium, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, or C 3 -C 6 cycloalkyl;

R 15 is independently hydrogen, C 1 -C 6 alkyl substituted with 0 to 2 R a s, C 1 -C 6 haloalkyl, or M a ;

wherein, R a is independently C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, halogen, C 1 -C 6 haloalkyl, C 1 -C 6 haloalkoxy, —CN, hydroxyl, —OM e , —SM e , —S(O) 2 M e , —C(O)NM f M g , —NM f M g , —N(M e )C(O)M h , —N(M e )S(O) 2 M h , —N(M e )C(O)OM h , —N(M e )C(O)NM f M g , or M b at each occurrence;

R 20 is independently hydrogen, halogen, —OH, —CN, —COOH, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, C 1 -C 6 haloalkoxy, C 2 -C 10 alkoxyalkyl, C 4 -C 20 alkoxyalkylalkynyl, C 2 -C 10 haloalkoxyalkyl, C 1 -C 6 hydroxyalkyl, C 3 -C 10 hydroxyalkylalkynyl, C 2 -C 10 hydroxyalkynyl, —B(R b )(R d ), —S(O) n1 R c , —N(R c ) 2 , —C(═O)N(R c ) 2 , —NHC(═O)R c , —NHC(═O)OR c , —NHC(═O)C(═O)N(R c ) 2 , —NHC(═O)C(═O)OR c , —NHC(═O)N(R c ) 2 , —NHC(═O)NR c C(═O)N(R c ) 2 , —NHC(═O)NR c S(O) 2 OR c , —NHC(═O)NR c S(O) 2 N(R c ) 2 , —NHC(═S)N(R c ) 2 —NHC(═NC≡N)NR c , NHC(═NC≡N)SR c , —NHS(O) n1 R c , M c , —(C 1 -C 6 alkylene)-B(R b )(R d ), —(C 1 -C 6 alkylene)-S(O) n1 R c , —(C 1 -C 6 alkylene)-N(R c ) 2 , —(C 1 -C 6 alkylene)-C(═O)N(R c ) 2 , —(C 1 -C 6 alkylene)-NHC(═O)R c , —(C 1 -C 6 alkylene)-NHC(═O)OR c , —(C 1 -C 6 alkylene)-NHC(═O)C(═O)N(R c ) 2 , —(C 1 -C 6 alkylene)-NHC(═O)N(R c ) 2 , —(C 1 -C 6 alkylene)-NHC(═O)NR c C(═O)N(R c ) 2 , —(C 1 -C 6 alkylene)-NHC(═O)NR c S(O) 2 OR c , —(C 1 -C 6 alkylene)-NHC(═O)NR c S(O) 2 N(R c ) 2 , —(C 1 -C 6 alkylene)-NHC(═S)N(R c ) 2 , —(C 1 -C 6 alkylene)-NHC(═N—C≡N)NR c , —(C 1 -C 6 alkylene)-NHC(═N—C≡N)SR c , —(C 1 -C 6 alkylene)-NHS(O) n1 R c , —(C 1 -C 6 alkylene)-M c , —CH≡CH—(C 1 -C 6 alkyl), —CH≡CH-M c , —OM c , —SM c , or —N(R c )M c at each occurrence;

R b and R d are each independently hydrogen, hydroxyl, or C 1 -C 6 alkyl;

R c is independently hydrogen, C 1 -C 6 alkyl, C 6 -C 10 aryl, 5-10 membered heteroaryl, 3-10 membered non-aromatic heterocyclic group, C 3 -C 10 cycloalkyl, or C 5 -C 10 cycloalkenyl, which are each independently unsubstituted or substituted with 1 or 2 groups of amino, hydroxyl, methoxy, C 1 -C 6 alkyl, C 3 -C 10 cycloalkyl, or CN when R c is not hydrogen;

M a , M b and M c are each independently C 6 -C 10 aryl, C 5 -C 10 heteroaryl, C 3 -C 10 non-aromatic heterocyclic group, C 3 -C 10 cycloalkyl, or C 3 -C 10 cycloalkenyl, which are each independently unsubstituted or substituted with 1-2 M d ;

M d is independently C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, halogen, C 1 -C 6 haloalkyl, —CN, oxo, —OM e , —OC(O)M h , —OC(O)NM f M g , —SM e , —S(O) 2 M e , —S(O) 2 NM f M g , —C(O)M e , —C(O)-5-10-membered monocyclic heterocyclic ring, —C(O)-5-10-membered monocyclic heteroaryl, —C(O)OM e , —C(O)NM f M g , —NM f M g , —N(M e )C(O)M h , —N(M e )S(O) 2 M h , —N(M e )C(O)OM h , —N(M e )C(O)NM f M g , —(C 1 -C 6 alkylene)-OM e , —(C 1 -C 6 alkylene)-OC(O)M h , —(C 1 -C 6 alkylene)-OC(O)NM f M g , —(C 1 -C 6 alkylene)-S(O) 2 M e , —(C 1 -C 6 alkylene)-S(O) 2 NM f M g , —(C 1 -C 6 alkylene)-C(O)M e , —(C 1 -C 6 alkylene)-C(O)OM e , —(C 1 -C 6 alkylene)-C(O)NM f M g , —(C 1 -C 6 alkylene)-NM f M g , —(C 1 -C 6 alkylene)-N(M e )C(O)M h , —(C 1 -C 6 alkylene)-N(M e )S(O) 2 M h , —(C 1 -C 6 alkylene)-N(M e )C(O)OM h , —(C 1 -C 6 alkylene)-N(M e )C(O)NM f M g , or —(C 1 -C 6 alkylene)-CN at each occurrence;

R 21 is each independently C 1 -C 6 alkyl, halogen, C 1 -C 6 haloalkyl, C 1 -C 6 haloalkoxy, C 3 -C 6 cycloalkyl, —OM e , —OC(O)M h , —OC(O)NM f M g , —SM e , —S(O) 2 M e , —S(O) 2 NM f M g , —C(O)M e , —C(O)OM e , —C(O)NM f M g , —NM f M g , —N(M e )C(O)M h , —N(M e )S(O) 2 M h , —N(M e )C(O)OM h or —N(M e )C(O)NM f M g at each occurrence;

M e , M f , and M g are independently hydrogen, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, or C 3 -C 6 cycloalkyl at each occurrence; and M h is independently C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, or C 3 -C 6 cycloalkyl at each occurrence;

n1 is independently 0, 1 or 2 at each occurrence;

n3 is independently 0, 1, 2 or 3 at each occurrence.

2. The compound according to claim 1 , or a pharmaceutically acceptable salt, stereoisomer, enantiomer, diastereomer, atropisomer, racemate, polymorphs, solvate or isotopically labeled compound thereof, wherein, the compound is selected from the group consisting of the compounds represented by formulae Ii and Ij:

wherein

R 13 is hydrogen, C 1 -C 6 alkyl, or C 3 -C 6 cycloalkyl;

X 2 is CH 2 , O, —S(O) n1 —, or —N(R 4 )—;

R 15 , R 20 , R 21 , R 4 , n1 and n3 are the same as defined in the formulae Ig and Ih of claim 1 .

3. The compound according to claim 1 , or a pharmaceutically acceptable salt, stereoisomer, enantiomer, diastereomer, atropisomer, racemate, polymorphs, solvate or isotopically labeled compound thereof, wherein, the compound is selected from the group consisting of the compounds represented by formulae Ik and Il:

wherein

X 2 is CH 2 , O, S or —N(Me)-;

R 21 is C 1 -C 6 alkyl, halogen, C 1 -C 6 haloalkyl, C 1 -C 6 haloalkoxy, C 1 -C 6 alkoxy, or C 3 -C 6 cycloalkyl;

n3 is 0, 1 or 2;

R 15 is C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, or C 1 -C 6 haloalkyl;

R 20 is the same as defined in the formulae Ig and Ih of claim 1 .

4. The compound according to claim 3 , or a pharmaceutically acceptable salt, stereoisomer, enantiomer, diastereomer, atropisomer, racemate, polymorphs, solvate or isotopically labeled compound thereof, wherein,

X 2 is CH 2 , O, S or —N(Me)-;

R 21 is halogen;

n3 is 0, 1 or 2;

R 15 is cyclopropyl, methyl, ethyl, propyl, isopropyl, or CF 3 ;

R 20 is

 or —NHC(═O)(C 1 -C 6 alkyl).

5. A compound represented by formula Im, In, lo, or Ip, or a pharmaceutically acceptable salt, stereoisomer, enantiomer, diastereomer, atropisomer, racemate, polymorphs, solvate or isotopically labeled compound thereof:

wherein

X 2 is CH 2 , O, —S(O) n1 —, or —N(R 4 )—;

R 4 is independently hydrogen, C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, —C(═O)(C 1 -C 6 alkyl), —S(O) 2 (C 1 -C 6 alkyl), —C(═O)(C 3 -C 6 cycloalkyl), or —S(O) 2 (C 3 -C 6 cycloalkyl);

R 15 is independently hydrogen, C 1 -C 6 alkyl substituted with 0 to 2 R a s, C 1 -C 6 haloalkyl, or M a ;

wherein, R a is independently C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, halogen, C 1 -C 6 haloalkyl, C 1 -C 6 haloalkoxy, —CN, hydroxyl, —OM e , —SM e , —S(O) 2 M e , —C(O)NM f M g , —NM f M g , —N(M e )C(O)M h , —N(M e )S(O) 2 M h , —N(M e )C(O)OM h , —N(M e )C(O)NM f M g , or M b at each occurrence:

R 20 is independently hydrogen, halogen, —OH, —CN, —COOH, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, C 1 -C 6 haloalkoxy, C 2 -C 10 alkoxyalkyl, C 4 -C 20 alkoxyalkylalkynyl, C 2 -C 10 haloalkoxyalkyl, C 1 -C 6 hydroxyalkyl, C 3 -C 10 hydroxyalkylalkynyl, C 2 -C 10 hydroxyalkynyl, —B(R b )(R d ), —S(O) n1 R c , —N(R c ) 2 , —C(═O)N(R c ) 2 , —NHC(═O)R c , —NHC(═O)OR c , —NHC(═O)C(═O)N(R c ) 2 , —NHC(═O)C(═O)OR c , —NHC(═O)N(R c ) 2 , —NHC(═O)NR c C(═O)N(R c ) 2 , —NHC(═O)NR c S(O) 2 OR c , —NHC(═O)NR c S(O) 2 N(R c ) 2 , —NHC(═S)N(R c ) 2 —NHC(═NC≡N)NR c , —NHC(═NC≡N)SR c , —NHS(O) n1 R c , M c , —(C 1 -C 6 alkylene)-B(R b )(R d ), —(C 1 -C 6 alkylene)-S(O) n1 R c , —(C 1 -C 6 alkylene)-N(R c ) 2 , —(C 1 -C 6 alkylene)-C(═O)N(R c ) 2 , —(C 1 -C 6 alkylene)-NHC(═O)R c , —(C 1 -C 6 alkylene)-NHC(═O)OR c , —(C 1 -C 6 alkylene)-NHC(═O)C(═O)N(R c ) 2 , —(C 1 -C 6 alkylene)-NHC(═O)N(R c ) 2 , —(C 1 -C 6 alkylene)-NHC(═O)NR c C(═O)N(R c ) 2 , —(C 1 -C 6 alkylene)-NHC(═O)NR c S(O) 2 OR c , —(C 1 -C 6 alkylene)-NHC(═O)NR c S(O) 2 N(R c ) 2 , —(C 1 -C 6 alkylene)-NHC(═S)N(R c ) 2 , —(C 1 -C 6 alkylene)-NHC(═N-CEN)NR c , —(C 1 -C 6 alkylene)-NHC(═N—C≡N)SR c , —(C 1 -C 6 alkylene)-NHS(O) n1 R c , —(C 1 -C 6 alkylene)-M c , —CH═CH—(C 1 -C 6 alkyl), —CH═CH-M c , —OM c , —SM c , or —N(R c )M c at each occurrence:

R b and R d are each independently hydrogen, hydroxyl, or C 1 -C 6 alkyl;

R c is independently hydrogen, C 1 -C 6 alkyl, C 6 -C 10 aryl, 5-10 membered heteroaryl, 3-10 membered non-aromatic heterocyclic group, C 3 -C 10 cycloalkyl, or C 5 -C 10 cycloalkenyl, which are each independently unsubstituted or substituted with 1 or 2 groups of amino, hydroxyl, methoxy, C 1 -C 6 alkyl, C 3 -C 10 cycloalkyl, or CN when R c is not hydrogen;

M a , M b and M c are each independently C 6 -C 10 aryl, C 5 -C 10 heteroaryl, C 3 -C 10 non-aromatic heterocyclic group, C 3 -C 10 cycloalkyl, or C 3 -C 10 cycloalkenyl, which are each independently unsubstituted or substituted with 1-2 M d ;

M d is independently C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, halogen, C 1 -C 6 haloalkyl, —CN, oxo, —OM e , —OC(O)M h , —OC(O)NM f M g , —SM e , —S(O) 2 M e , —S(O) 2 NM f M g , —C(O)M e , —C(O)-5-10-membered monocyclic heterocyclic ring, —C(O)-5-10-membered monocyclic heteroaryl, —C(O)OM e , —C(O)NM f M g , —NM f M g , —N(M e )C(O)M h , —N(M e )S(O) 2 M h , —N(M e )C(O)OM h , —N(M e )C(O)NM f M g , —(C 1 -C 6 alkylene)-OM e , —(C 1 -C 6 alkylene)-OC(O)M h , —(C 1 -C 6 alkylene)-OC(O)NM f M g , —(C 1 -C 6 alkylene)-S(O) 2 M e , —(C 1 -C 6 alkylene)-S(O) 2 NM f M g , —(C 1 -C 6 alkylene)-C(O)M e , —(C 1 -C 6 alkylene)-C(O)OM e , —(C 1 -C 6 alkylene)-C(O)NM f M g , —(C 1 -C 6 alkylene)-NM f M g , —(C 1 -C 6 alkylene)-N(M e )C(O)M h , —(C 1 -C 6 alkylene)-N(M e )S(O) 2 M h , —(C 1 -C 6 alkylene)-N(M e )C(O)OM h , —(C 1 -C 6 alkylene)-N(M e )C(O)NM f M g , or —(C 1 -C 6 alkylene)-CN at each occurrence:

R 21 is each independently C 1 -C 6 alkyl, halogen, C 1 -C 6 haloalkyl, C 1 -C 6 haloalkoxy, C 3 -C 6 cycloalkyl, —OM e , —OC(O)M h , —OC(O)NM f M g , —SM e , —S(O) 2 M e , —S(O) 2 NM f M g , —C(O)M e , —C(O)OM e , —C(O)NM f M g , —NM f M g , —N(M e )C(O)M h , —N(M e )S(O) 2 M h , —N(M e )C(O)OM h or —N(M e )C(O)NM f M g at each occurrence:

M e , M f , and M g are independently hydrogen, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, or C 3 -C 6 cycloalkyl at each occurrence; and M h is independently C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, or C 3 -C 6 cycloalkyl at each occurrence;

n1 is independently 0, 1 or 2 at each occurrence;

n3 is are independently 0, 1, 2 or 3 at each occurrence,

W is a benzene ring or a C 5 -C 6 heteroaromatic ring.

6. A compound, or a pharmaceutically acceptable salt, stereoisomer, enantiomer, diastereomer, atropisomer, racemate, polymorphs, solvate or isotopically labeled compound thereof, wherein, the compound is selected from the group consisting of

7. A pharmaceutical composition comprising a therapeutically effective amount of the compound according to claim 1 , or a pharmaceutically acceptable salt, stereoisomer, enantiomer, diastereomer, atropisomer, racemate, polymorphs, solvate or isotopically labeled compound, and a pharmaceutically acceptable carrier, diluent or excipient.

8. The pharmaceutical composition according to claim 7 , wherein the pharmaceutical composition further comprises at least one therapeutic agent.

9. A method of treating a disease, disorder or condition in a subject, comprising:

administrating the compound, a pharmaceutically acceptable salt, stereoisomer, enantiomer, diastereomer, atropisomer, racemate, polymorphs, solvate or isotopically labeled compound thereof according to claim 1 to the subject,

wherein the disease, disorder or condition is selected from the group consisting of acoustic neuroma, acute leukemia, basal cell carcinoma, cholangiocarcinoma, bladder cancer, brain cancer, breast cancer, bronchial cancer, Burkitt's lymphoma, cervical cancer, chondrosarcoma, chordoma, choriocarcinoma, chronic leukemia, colon cancer, colorectal cancer, craniopharyngioma, cystadenocarcinoma, diffuse large B-cell lymphoma, undesirable proliferative changes, embryonic cancer, endometrial cancer, epithelial cancer, erythroleukemia, esophageal cancer, estrogen receptor-positive breast cancer, essential thrombocythemia, Ewing's Sarcoma, fibrosarcoma, follicular lymphoma, germ cell testicular cancer, glioma, glioblastoma, gliosarcoma, heavy chain disease, hemangioblastoma, liver cancer, hepatocellular carcinoma, hormone-insensitive prostate cancer, leiomyosarcoma, liposarcoma, lung cancer, lymphatic endothelial sarcoma, lymphangiosarcoma, lymphoblastic leukemia, Lymphoma, lymphoma medullary carcinoma, medulloblastoma, melanoma, meningioma, mesothelioma, multiple myeloma, Myelogenous leukemia, myeloma, myxosarcoma, neuroblastoma, NUT midline carcinoma, non-small cell lung cancer, oligodendroglioma, oral cancer, osteogenic sarcoma, ovarian cancer, pancreatic cancer, papillary adenocarcinoma, papillary cancer, pineal gland tumor, polycythemia vera, prostate cancer, rectal cancer, renal cell carcinoma, retinoblastoma, rhabdomyosarcoma, sarcoma, sebaceous carcinoma, seminoma, skin cancer, stomach cancer, squamous cell carcinoma, synovial tumor, spiroma, thyroid cancer, primary macroglobulinemia, testicular tumor, uterine cancer and nephroblastoma,

alternatively, the disease, disorder or condition is selected from the group consisting of a metabolic disease, a neurodegenerative disease and an inflammation.

10. A method of treating a disease, disorder or condition in a subject, comprising:

administrating the pharmaceutical composition according to claim 7 to the subject, wherein the disease, disorder or condition is selected from the group consisting of acoustic neuroma, basal cell carcinoma, cholangiocarcinoma, bladder cancer, brain cancer, breast cancer, bronchial cancer, Burkitt's lymphoma, cervical cancer, chondrosarcoma, chordoma, choriocarcinoma, chronic leukemia, chronic lymphocytic leukemia, chronic myeloid leukemia, chronic myelogenous leukemia, colon cancer, colorectal cancer, craniopharyngioma, cystadenocarcinoma, diffuse large B-cell lymphoma, undesirable proliferative changes, embryonic cancer, endometrial cancer, epithelial cancer, erythroleukemia, esophageal cancer, estrogen receptor-positive breast cancer, essential thrombocythemia, Ewing's Sarcoma, fibrosarcoma, follicular lymphoma, germ cell testicular cancer, glioma, glioblastoma, gliosarcoma, heavy chain disease, hemangioblastoma, liver cancer, hepatocellular carcinoma, hormone-insensitive prostate cancer, leiomyosarcoma, liposarcoma, lung cancer, lymphatic endothelial sarcoma, lymphangiosarcoma, lymphoblastic leukemia, Lymphoma, lymphoma, medullary carcinoma, medulloblastoma, melanoma, meningioma, mesothelioma, multiple myeloma, Myelogenous leukemia, myeloma, myxosarcoma, neuroblastoma, NUT midline carcinoma, non-small cell lung cancer, oligodendroglioma, oral cancer, osteogenic sarcoma, ovarian cancer, pancreatic cancer, papillary adenocarcinoma, papillary cancer, pineal gland tumor, polycythemia vera, prostate cancer, rectal cancer, renal cell carcinoma, retinoblastoma, rhabdomyosarcoma, sarcoma, sebaceous carcinoma, seminoma, skin cancer, stomach cancer, squamous cell carcinoma, synovial tumor, spiroma, thyroid cancer, primary macroglobulinemia, testicular tumor, uterine cancer and nephroblastoma,

alternatively, the disease, disorder or condition is selected from the group consisting of a metabolic disease, a neurodegenerative disease and an inflammation.

11. The pharmaceutical composition according to claim 8 , wherein the at least one therapeutic agent comprised in the pharmaceutical composition is selected from the group consisting of anticancer agents, immunomodulators, antiallergic agents, antiemetics, pain relievers, cytoprotective agents, and combinations thereof.

12. A pharmaceutical composition comprising a therapeutically effective amount of the compound according to claim 6 , or a pharmaceutically acceptable salt, stereoisomer, enantiomer, diastereomer, atropisomer, racemate, polymorphs, solvate or isotopically labeled compound thereof, and a pharmaceutically acceptable carrier, diluent or excipient.

13. A method of treating a disease, disorder or condition in a subject, comprising

administrating the compound, a pharmaceutically acceptable salt, stereoisomer, enantiomer, diastereomer, atropisomer, racemate, polymorphs, solvate or isotopically labeled compound thereof according to claim 6 to the subject,

wherein the disease, disorder or condition is selected from the group consisting of acoustic neuroma, acute leukemia, basal cell carcinoma, cholangiocarcinoma, bladder cancer, brain cancer, breast cancer, bronchial cancer, Burkitt's lymphoma, cervical cancer, chondrosarcoma, chordoma, choriocarcinoma, chronic leukemia, colon cancer, colorectal cancer, craniopharyngioma, cystadenocarcinoma, diffuse large B-cell lymphoma, undesirable proliferative changes, embryonic cancer, endometrial cancer, epithelial cancer, erythroleukemia, esophageal cancer, estrogen receptor-positive breast cancer, essential thrombocythemia, Ewing's Sarcoma, fibrosarcoma, follicular lymphoma, germ cell testicular cancer, glioma, glioblastoma, gliosarcoma, heavy chain disease, hemangioblastoma, liver cancer, hepatocellular carcinoma, hormone-insensitive prostate cancer, leiomyosarcoma, liposarcoma, lung cancer, lymphatic endothelial sarcoma, lymphangiosarcoma, lymphoblastic leukemia, Lymphoma, lymphoma, medullary carcinoma, medulloblastoma, melanoma, meningioma, mesothelioma, multiple myeloma, Myelogenous leukemia, myeloma, myxosarcoma, neuroblastoma, NUT midline carcinoma, non-small cell lung cancer, oligodendroglioma, oral cancer, osteogenic sarcoma, ovarian cancer, pancreatic cancer, papillary adenocarcinoma, papillary cancer, pineal gland tumor, polycythemia vera, prostate cancer, rectal cancer, renal cell carcinoma, retinoblastoma, rhabdomyosarcoma, sarcoma, sebaceous carcinoma, seminoma, skin cancer, stomach cancer, squamous cell carcinoma, synovial tumor, spiroma, thyroid cancer, primary macroglobulinemia, testicular tumor, uterine cancer and nephroblastoma,

alternatively, the disease, disorder or condition is selected from the group consisting of a metabolic disease, a neurodegenerative disease and an inflammation.

14. A method of treating a disease, disorder or condition in a subject, comprising

administrating the pharmaceutical composition according to claim 12 to the subject, wherein the disease, disorder or condition is selected from the group consisting of acoustic neuroma, acute leukemia, basal cell carcinoma, cholangiocarcinoma, bladder cancer, brain cancer, breast cancer, bronchial cancer, Burkitt's lymphoma, cervical cancer, chondrosarcoma, chordoma, choriocarcinoma, chronic leukemia, chronic lymphocytic leukemia, chronic myeloid leukemia, chronic myelogenous leukemia, colon cancer, colorectal cancer, craniopharyngioma, cystadenocarcinoma, diffuse large B-cell lymphoma, undesirable proliferative changes, embryonic cancer, endometrial cancer, epithelial cancer, erythroleukemia, esophageal cancer, estrogen receptor-positive breast cancer, essential thrombocythemia, Ewing's Sarcoma, fibrosarcoma, follicular lymphoma, germ cell testicular cancer, glioma, glioblastoma, gliosarcoma, heavy chain disease, hemangioblastoma, liver cancer, hepatocellular carcinoma, hormone-insensitive prostate cancer, leiomyosarcoma, liposarcoma, lung cancer, lymphatic endothelial sarcoma, lymphangiosarcoma, lymphoblastic leukemia, Lymphoma, lymphoma, medullary carcinoma, medulloblastoma, melanoma, meningioma, mesothelioma, multiple myeloma, Myelogenous leukemia, myeloma, myxosarcoma, neuroblastoma, NUT midline carcinoma, non-small cell lung cancer, oligodendroglioma, oral cancer, osteogenic sarcoma, ovarian cancer, pancreatic cancer, papillary adenocarcinoma, papillary cancer, pineal gland tumor, polycythemia vera, prostate cancer, rectal cancer, renal cell carcinoma, retinoblastoma, rhabdomyosarcoma, sarcoma, sebaceous carcinoma, seminoma, skin cancer, stomach cancer, squamous cell carcinoma, synovial tumor, spiroma, thyroid cancer, primary macroglobulinemia, testicular tumor, uterine cancer and nephroblastoma,

alternatively, the disease, disorder or condition is selected from the group consisting of a metabolic disease, a neurodegenerative disease and an inflammation.

15. A pharmaceutical composition comprising a therapeutically effective amount of the compound according to claim 5 , or a pharmaceutically acceptable salt, stereoisomer, enantiomer, diastereomer, atropisomer, racemate, polymorphs, solvate or isotopically labeled compound thereof, and a pharmaceutically acceptable carrier, diluent or excipient.

16. A method of treating a disease, disorder or condition in a subject, comprising

administrating the compound, a pharmaceutically acceptable salt, stereoisomer, enantiomer, diastereomer, atropisomer, racemate, polymorphs, solvate or isotopically labeled compound thereof according to claim 5 to the subject,

wherein the disease, disorder or condition is selected from the group consisting of acoustic neuroma, acute leukemia, basal cell carcinoma, cholangiocarcinoma, bladder cancer, brain cancer, breast cancer, bronchial cancer, Burkitt's lymphoma, cervical cancer, chondrosarcoma, chordoma, choriocarcinoma, chronic leukemia, chronic lymphocytic leukemia, chronic myeloid leukemia, chronic myelogenous leukemia, colon cancer, colorectal cancer, craniopharyngioma, cystadenocarcinoma, diffuse large B-cell lymphoma, undesirable proliferative changes, embryonic cancer, endometrial cancer, epithelial cancer, erythroleukemia, esophageal cancer, estrogen receptor-positive breast cancer, essential thrombocythemia, Ewing's Sarcoma, fibrosarcoma, follicular lymphoma, germ cell testicular cancer, glioma, glioblastoma, gliosarcoma, heavy chain disease, hemangioblastoma, liver cancer, hepatocellular carcinoma, hormone-insensitive prostate cancer, leiomyosarcoma, liposarcoma, lung cancer, lymphatic endothelial sarcoma, lymphangiosarcoma, lymphoblastic leukemia, Lymphoma, lymphoma, medullary carcinoma, medulloblastoma, melanoma, meningioma, mesothelioma, multiple myeloma, Myelogenous leukemia, myeloma, myxosarcoma, neuroblastoma, NUT midline carcinoma, non-small cell lung cancer, oligodendroglioma, oral cancer, osteogenic sarcoma, ovarian cancer, pancreatic cancer, papillary adenocarcinoma, papillary cancer, pineal gland tumor, polycythemia vera, prostate cancer, rectal cancer, renal cell carcinoma, retinoblastoma, rhabdomyosarcoma, sarcoma, sebaceous carcinoma, seminoma, skin cancer, stomach cancer, squamous cell carcinoma, synovial tumor, spiroma, thyroid cancer, primary macroglobulinemia, testicular tumor, uterine cancer and nephroblastoma,

alternatively, the disease, disorder or condition is selected from the group consisting of a metabolic disease, a neurodegenerative disease and an inflammation.

17. A method of treating a disease, disorder or condition in a subject, comprising

administrating the pharmaceutical composition according to claim 15 to the subject, wherein the disease, disorder or condition is selected from the group consisting of acoustic neuroma, acute leukemia, basal cell carcinoma, cholangiocarcinoma, bladder cancer, brain cancer, breast cancer, bronchial cancer, Burkitt's lymphoma, cervical cancer, chondrosarcoma, chordoma, choriocarcinoma, chronic leukemia, colon cancer, colorectal cancer, craniopharyngioma, cystadenocarcinoma, diffuse large B-cell lymphoma, undesirable proliferative changes, embryonic cancer, endometrial cancer, epithelial cancer, erythroleukemia, esophageal cancer, estrogen receptor-positive breast cancer, essential thrombocythemia, Ewing's Sarcoma, fibrosarcoma, follicular lymphoma, germ cell testicular cancer, glioma, glioblastoma, gliosarcoma, heavy chain disease, hemangioblastoma, liver cancer, hepatocellular carcinoma, hormone-insensitive prostate cancer, leiomyosarcoma, liposarcoma, lung cancer, lymphatic endothelial sarcoma, lymphangiosarcoma, lymphoblastic leukemia, Lymphoma, lymphoma, medullary carcinoma, medulloblastoma, melanoma, meningioma, mesothelioma, multiple myeloma, Myelogenous leukemia, myeloma, myxosarcoma, neuroblastoma, NUT midline carcinoma-(—NM), non-small cell lung cancer, oligodendroglioma, oral cancer, osteogenic sarcoma, ovarian cancer, pancreatic cancer, papillary adenocarcinoma, papillary cancer, pineal gland tumor, polycythemia vera, prostate cancer, rectal cancer, renal cell carcinoma, retinoblastoma, rhabdomyosarcoma, sarcoma, sebaceous carcinoma, seminoma, skin cancer, stomach cancer, squamous cell carcinoma, synovial tumor, spiroma, thyroid cancer, primary macroglobulinemia, testicular tumor, uterine cancer and nephroblastoma,

alternatively, the disease, disorder or condition is selected from the group consisting of a metabolic disease, a neurodegenerative disease and an inflammation.